ArticleBMC cancer2020
Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China.
Zhi Peng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
12 papers cite it
this paperpooled itcites it